Combination of Targeted Therapies for Colorectal Cancer Treatment
Molecular Pharmaceutics · 04.09.2023 · 20 (9) · 4537-4545
DOI: 10.1021/acs.molpharmaceut.3c00224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 14.08.2023. Verfasst von Elodie Péraudeau und 9 weiteren Autor:innen. Beteiligte Einrichtung: Equipe Labellisée Ligue Contre le Cancer, Université de Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), 4 r…. Hauptthemen laut MEDLINE: Prodrugs, Antineoplastic Agents, Immunoconjugates, Colorectal Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Ligue Contre le Cancer, Soci?t? Nationale Fran?aise de Gastro-Ent?rologie, Conseil R?gional Aquitaine.
Abstract (Originalsprache)
The design of innovative therapeutic strategies enabling the selective destruction of tumor cells while sparing healthy tissues remains highly challenging in cancer therapy. Here, we show that the combination of two targeted therapies, including bevacizumab (Bev), and a β-glucuronidase-responsive albumin-binding prodrug of monomethyl auristatin E (MMAE), is efficient for the treatment of colorectal cancer implanted in mice. This combined therapy produces a therapeutic activity superior to that of the association of FOLFOX and Bev currently used to treat patients with this pathology. The increased anticancer efficacy is due to either a synergistic or an additive effect between Bev and MMAE selectively released from the glucuronide prodrug in the tumor microenvironment. Since numerous drug delivery systems such as antibody-drug conjugates employ MMAE as a cytotoxic payload, this finding may be of great interest for improving their therapeutic index by combining them with Bev, particularly for the therapy of colorectal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Equipe Labellisée Ligue Contre le Cancer, Université de Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), 4 rue Michel-Brunet, TSA 51106, 86073 Poitiers, Cedex 9, France.
- CHU de Poitiers, 86021 Poitiers, France.
- Department of Medical Oncology, Poitiers University Hospital, 86021 Poitiers, France.
- Department of Gastroenterology and Hepatology, Poitiers University Hospital, 86021 Poitiers, France.
ORCID-Profile: Pauline Poinot, Sébastien Papot
Förderung
- Ligue Contre le Cancer
- Soci?t? Nationale Fran?aise de Gastro-Ent?rologie
- Conseil R?gional Aquitaine
Zitieren
APA
Péraudeau, E., Renoux, B., Emambux, S., Poinot, P., Châtre, R., Thoreau, F., Riss Yaw, B., Tougeron, D., Clarhaut, J., & Papot, S. (2023). Combination of Targeted Therapies for Colorectal Cancer Treatment. Molecular Pharmaceutics, 20(9), 4537-4545. https://doi.org/10.1021/acs.molpharmaceut.3c00224
Vancouver
Péraudeau E, Renoux B, Emambux S, Poinot P, Châtre R, Thoreau F, et al. Combination of Targeted Therapies for Colorectal Cancer Treatment. Molecular Pharmaceutics. 2023;20(9):4537-4545. doi:10.1021/acs.molpharmaceut.3c00224
BibTeX
@article{Praudeau2023,
author = {Péraudeau, Elodie and Renoux, Brigitte and Emambux, Sheik and Poinot, Pauline and Châtre, Rémi and Thoreau, Fabien and Riss Yaw, Benjamin and Tougeron, David and Clarhaut, Jonathan and Papot, Sébastien},
title = {Combination of Targeted Therapies for Colorectal Cancer Treatment},
journal = {Molecular Pharmaceutics},
year = {2023},
volume = {20},
number = {9},
pages = {4537--4545},
doi = {10.1021/acs.molpharmaceut.3c00224}
}
EUVIMED